An intranasal live-attenuated vaccine to combat lassa virus infection

Active Grant Awarded

Award ID
R21AI198928
Recipient
Awarding agency
Obligated
$238,463

Award facts

Assistance listing
93.855 Allergy and Infectious Diseases Research
Completion date 10% complete
Place of performance
San Antonio, TX 78227, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, awarded Texas Biomedical Research Institute, doing business as Southwest Foundation for Biomedical Research, $238,463 on September 14, 2026, under grant R21AI198928 in the Allergy and Infectious Diseases Research program (CFDA 93.855). The full $238,463 is obligated.

The award funds research testing whether recombinant Newcastle disease virus expressing codon-optimized Lassa virus glycoprotein (GPC) and/or nucleoprotein (NP) can serve as a safe, immunogenic, and protective intranasal live-attenuated vaccine against Lassa fever. The application cites prior work showing that these constructs are stable and fully attenuated and that a single intranasal dose protected against subsequent lethal challenge with wild-type homologous viruses. The source notes that no FDA-approved Lassa virus vaccine currently exists.

Work is performed in San Antonio, Texas 78227, with an ultimate completion date of August 31, 2028. The source identifies no sub-recipients for this award.

Description

Abstract
Lassa virus (LASV) is endemic to west africa where IT infects several hundred thousand individuals yearly resulting in a high number (~20%) of lassa fever (LF) cases associated with high morbidity and mortality. There are no united states (US) food and drug administration (FDA)-approved LASV vaccines and current anti-LASV therapy is limited to an off-label use of ribavirin, which has limited efficacy. LF has been included on the revised list of priority diseases from the who R & D blueprint, underscoring an urgent need for vaccines to combat LF. We have documented that recombinant forms of newcastle disease virus (RNDV) expressing the glycoprotein surface protein of different viruses are stable and fully attenuated but able to provide complete protection, upon a single intranasal (in) dose, against a subsequent lethal challenge with wild-type (WT) forms of homologous viruses. The central goal of this application is to test the novel hypothesis that, similar to other RNDV- based in live-attenuated vaccines (LAV), RNDV expressing, individually or together, codon optimized (CO) LASV glycoprotein (GPC) and/or CO nucleoprotein (NP), can be implemented as a safe, immunogenic, and protective in LAV to combat LF disease caused by LASV infection. Our hypothesis is supported by multiple findings: 1) avirulent NDV strains (e.g., lasota, this application) have a long track record of safety in humans; 2) there is no pre-existing immunity to avian-based NDV in the human population; 3) NDV is able to induce robust innate and adaptive immune responses against the foreign antigen expressed in the RNDV; 4) immunization with rndvs expressing foreign viral antigens has been shown to provide, upon a single in administration, protection against a subsequent lethal challenge with homologous viruses; 5) NDV can grow efficiently to high titers in US FDA-approved substrates (e.g., vero cells and chicken embryonated eggs); 6) rndvs expressing foreign viral antigens have been shown to have an excellent profile of genetic and phenotypic stability in vitro and in vivo; 7) we will use, for the first time, CO forms of LASV GPC (GPCCO) and/or NP (NPCO) to enhance protein expression and, therefore, increase immunogenicity and protection efficacy; and 8) our RNDV- based in LAV will express the two major antigenic proteins of LASV (GPC and NP) to broaden immunogenicity and protection efficacy. The generation and initial characterization of our RNDV-based in LAV in this application represents a necessary first step to demonstrate the safety, immunogenicity, and protection efficacy before testing in a non-human primate (NHP) model of LASV infection (outside the scope of this application). To demonstrate our novel hypothesis, we will generate and characterize RNDV expressing, individually or together, GPCCO and/or NPCO in vitro (aim 1) to prove they are attenuated but able to induce protective immune responses, upon a single in immunization, against a lethal challenge with LASV in the hartley guinea PIG (GP) model of LASV infection (aim 2). This will be the first time that an NDV-based approach will be used as an in LAV for the treatment of LF disease caused by LASV infection.

Quick answers

Who received award R21AI198928?

R21AI198928 was awarded to Texas Biomedical Research Institute by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 14, 2026.

How much is award R21AI198928 worth?

$238,463 has been obligated on R21AI198928.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award